Delivery of Nanoparticles and Macromolecules across the Blood–Brain Barrier
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Treatment of brain‐related diseases is challenging due to the presence of the blood–brain barrier (BBB), a hurdle that prevents most foreign matter from entering the brain. While macromolecules and nanoparticles represent an increasing fraction of the therapeutic landscape in general, their limited ability to cross the BBB has hindered their clinical impact in treating diseases of the central nervous system. Here, the various routes for entry of macromolecular therapeutics into the brain are discussed, as well as the methods used to enhance their transport. Particular emphasis is placed on highlighting quantitative trends and mechanistic insights into how the macromolecular transport can be improved, discussing novel enhancement strategies, and identifying areas in need of more detailed investigations. Overall, this review shows several promising advances and continued progress toward a more complete understanding of how macromolecule and nanoparticle design and delivery strategy characteristics can be leveraged to improve the treatment of brain diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
The blood-brain barrier in systemic inflammation
Varatharaj, A., & Galea, I. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.03.010 · Cited by 1,172
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794
Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox175 · Cited by 746
A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes
Nakagawa, S., Deli, M. A., Kawaguchi, H., Shimizudani, T., Shimono, T., Kittel, Á., Tanaka, K., & Niwa, M. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2008.12.002 · Cited by 728
Campisi, M., Shin, Y., Osaki, T., Hajal, C., Chiono, V., & Kamm, R. D. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.07.014 · Cited by 718
CNS Delivery Via Adsorptive Transcytosis
Hervé, F., Ghinea, N., & Scherrmann, J.-M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9055-2 · Cited by 676
The blood-brain barrier: an engineering perspective
Wong, A. D., Ye, M., Levy, A. F., Rothstein, J. D., Bergles, D. E., & Searson, P. C. (2013) · Frontiers in Neuroengineering · doi:10.3389/fneng.2013.00007 · Cited by 662
Intranasal Drug Delivery: How, Why and What For?
Pires, A., Fortuna, A., Alves, G., & Falcão, A. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3nc79 · Cited by 641
Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J. O., Lau, W., Tissot, A. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.061 · Cited by 622
Cited by
Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery
Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., & Wu, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01605-4 · Cited by 259
“To penetrate the central nervous system (CNS), NPs need to be taken up by BBB ECs via receptor-mediated endocytosis and exocytosed on the opposite side [106, 120].”
BackgroundFrontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier
Teleanu, R. I., Preda, M. D., Niculescu, A.-G., Vladâcenco, O., Radu, C. I., Grumezescu, A. M., & Teleanu, D. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050987 · Cited by 200
Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases
Masoudi Asil, S., Ahlawat, J., Guillama Barroso, G., & Narayan, M. (2020) · Biomaterials Science · doi:10.1039/d0bm00809e · Cited by 181
BBB pathophysiology–independent delivery of siRNA in traumatic brain injury
Li, W., Qiu, J., Li, X.-L., Aday, S., Zhang, J., Conley, G., Xu, J., Joseph, J., Lan, H., Langer, R., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd6889 · Cited by 160
Metadata
- Authors
- Nowak, M., Helgeson, M. E., & Mitragotri, S.
- Venue
- Advanced Therapeutics
- Publisher
- Wiley
- Published
- 2019-09-18
- Volume
- 3
- Issue
- 1
- ISSN
- 2366-3987 (ISSN-L)
- OpenAlex
- W2974177021
- Cited by
- 60
- References
- 17
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.